CCL2, CCL8, CXCL12 chemokines in resectable non-small cell lung cancer (NSCLC)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F23%3A10001185" target="_blank" >RIV/00064190:_____/23:10001185 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/23:10453593 RIV/00216208:11120/23:43925032

Výsledek na webu

<a href="https://biomed.papers.upol.cz/artkey/bio-202304-0004_ccl2-ccl8-cxcl12-chemokines-in-resectable-non-small-cell-lung-cancer-nsclc.php" target="_blank" >https://biomed.papers.upol.cz/artkey/bio-202304-0004_ccl2-ccl8-cxcl12-chemokines-in-resectable-non-small-cell-lung-cancer-nsclc.php</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/BP.2022.050" target="_blank" >10.5507/BP.2022.050</a>

Jazyk výsledku

angličtina

Název v původním jazyce

CCL2, CCL8, CXCL12 chemokines in resectable non-small cell lung cancer (NSCLC)

Popis výsledku v původním jazyce

Background. Complex networks of chemokines are part of the immune reaction targeted against tumor cells. Chemokines influence cancer growth. It is unclear whether the concentrations of chemokines at the time of NSCLC (non-small cell lung cancer) diagnosis differ from healthy controls and reflect the extent of NSCLC. Aims. To compare chemokine concentrations (CCL2, CCL8, CXCL12) in the plasma of patients with resectable NSCLC to those without cancer. To determine whether the chemokine concentrations differ relative to the stage of disease. Methods. Sixty-nine patients undergoing surgery for proven/suspected NSCLC were enrolled. They underwent standard diagnostic and staging procedures to determine resectability, surgery was performed. Forty-two patients were diagnosed with NSCLC, while 27patients had benign lung lesions and functioned as the control group. Chemokine concentrations in peripheral blood were assessed using ELISA. Parametric statistics were used for the analysis of results. Results. There were no differences in plasma chemokine concentrations in NSCLC patients compared to controls. CXCL12 concentrations correlated positively with tumor extent expressed as clinical stage, (mean values: stage I 5.08 ng/mL, SEM 0.59; stage II and IIIA 7.82 ng/mL; SEM 1.06; P=0.022). Patients with NSCLC stages II+IIIA had significantly higher CXCL12 concentrations than controls (mean values: stage II+IIIA 7.82 ng/mL; SEM 1.06; controls 5.3 ng/mL; SEM 0.46; P=0.017). Conclusion. CXCL12 was related to tumor growth and could potentially be used as a biomarker of advanced disease. (C) 2023 The Authors.

Název v anglickém jazyce

CCL2, CCL8, CXCL12 chemokines in resectable non-small cell lung cancer (NSCLC)

Popis výsledku anglicky

Background. Complex networks of chemokines are part of the immune reaction targeted against tumor cells. Chemokines influence cancer growth. It is unclear whether the concentrations of chemokines at the time of NSCLC (non-small cell lung cancer) diagnosis differ from healthy controls and reflect the extent of NSCLC. Aims. To compare chemokine concentrations (CCL2, CCL8, CXCL12) in the plasma of patients with resectable NSCLC to those without cancer. To determine whether the chemokine concentrations differ relative to the stage of disease. Methods. Sixty-nine patients undergoing surgery for proven/suspected NSCLC were enrolled. They underwent standard diagnostic and staging procedures to determine resectability, surgery was performed. Forty-two patients were diagnosed with NSCLC, while 27patients had benign lung lesions and functioned as the control group. Chemokine concentrations in peripheral blood were assessed using ELISA. Parametric statistics were used for the analysis of results. Results. There were no differences in plasma chemokine concentrations in NSCLC patients compared to controls. CXCL12 concentrations correlated positively with tumor extent expressed as clinical stage, (mean values: stage I 5.08 ng/mL, SEM 0.59; stage II and IIIA 7.82 ng/mL; SEM 1.06; P=0.022). Patients with NSCLC stages II+IIIA had significantly higher CXCL12 concentrations than controls (mean values: stage II+IIIA 7.82 ng/mL; SEM 1.06; controls 5.3 ng/mL; SEM 0.46; P=0.017). Conclusion. CXCL12 was related to tumor growth and could potentially be used as a biomarker of advanced disease. (C) 2023 The Authors.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30203 - Respiratory systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BIOMEDICAL PAPERS-OLOMOUC

ISSN

1213-8118

e-ISSN

—

Svazek periodika

167

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

335-339

Kód UT WoS článku

000917083600001

EID výsledku v databázi Scopus

2-s2.0-85179772822